Abstract
Background A range of rare mutations involving micro-deletion or -duplication of genetic material (copy number variants (CNVs)) have been associated with high neurodevelopmental and psychiatric risk (ND-CNVs). Irritability is frequently observed in childhood neurodevelopmental conditions, yet its aetiology is largely unknown. Genetic variation may play a role, but there is a sparsity of studies investigating presentation of irritability in young people with ND-CNVs.
Aims This study aimed to investigate whether there is a difference in irritability in young people with rare ND-CNVs compared to those without ND-CNVs, and to what extent irritability is associated with psychiatric diagnoses and cognitive ability (IQ).
Methods Irritability and broader psychopathology was assessed in 485 young people with ND-CNVs and 164 sibling controls, using the child and adolescent psychiatric assessment (CAPA). Autism was assessed using the Social Communication Questionnaire (SCQ), and Intelligence Quotient (IQ) by the Wechsler Abbreviated Scale of Intelligence (WASI).
Results 54% of young people with ND-CNVs met the threshold for irritability; significantly more than controls (OR = 3.77, CI = 3.07-7.90, p= 5.31 x 10-11). When controlling for the presence of other psychiatric comorbidities, ND-CNV status was still associated with irritability. There was no evidence for a relationship between irritability and IQ.
Conclusions Irritability is an important aspect of the clinical picture in young people with ND-CNVs. This work shows that genetic variation is associated with irritability in young people with ND-CNVs, independent of psychiatric comorbidities or IQ impairment. Clinicians should be aware of this increased risk to inform management and interventions.
Competing Interest Statement
JH, SC, JW, PH declaration of interest: none. DS reports a grant from Sarepta Therapeutics outside the scope of this work. MO reports grants from Akrivia Health and Takeda Pharmaceuticals outside the scope of the present work. MvdB reports a grant from Takeda Pharmaceuticals outside the scope of the present work.
Funding Statement
This work was supported by the MRC (DS grant numbers: MR/TO33045/1, PH grant numbers: MR/T033045/1, MO grant numbers: MR/T033045/1, MR/N022572/1, MvdB grant numbers: MR/T033045/1, MR/N022572/1), the UK Medical Research Council (JW grant numbers: MR/L011166/1), the UK Medical Research Foundation (JW grant numbers: MR/N022572/1), Horizon 2020 (DS grant numbers: 847826), Medical Research Foundation Fellowship (SC grant: MRF-058-0015-F-CHAW) and the NIMH (PH, MO and MvdB grant number: U01MH119758).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All procedures involving human subjects/patients were granted ethical approval by the appropriate university and National Health Service (NHS) ethics and research and development committees; the NHS London Queen Square research ethics committee (14/LO/1069) and South East Wales Research Ethics Committee (09/WSE04/22).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵# IMAGINE-ID consortium members listed in additional supplement
Declaration of Interest Statement: JH, SC, JW, PH declaration of interest: none. DS reports a grant from Sarepta Therapeutics outside the scope of this work. MO reports grants from Akrivia Health and Takeda Pharmaceuticals outside the scope of the present work. MvdB reports a grant from Takeda Pharmaceuticals outside the scope of the present work.
Funding Statement: This work was supported by the MRC (DS grant numbers: MR/TO33045/1, PH grant numbers: MR/T033045/1, MO grant numbers: MR/T033045/1, MR/N022572/1, MvdB grant numbers: MR/T033045/1, MR/N022572/1), the UK Medical Research Council (JW grant numbers: MR/L011166/1), the UK Medical Research Foundation (JW grant numbers: MR/N022572/1), Horizon 2020 (DS grant numbers: 847826), Medical Research Foundation Fellowship (SC grant: MRF-058-0015-F-CHAW) and the NIMH (PH, MO and MvdB grant number: U01MH119758).
Data availability: Data are held at Cardiff University. The data are available upon request. Please contact Prof. van den Bree (vandenbreemb{at}cardiff.ac.uk) for any data requests.
Data Availability
Data are held at Cardiff University. The data are available upon request. Please contact Prof. van den Bree (vandenbreemb{at}cardiff.ac.uk) for any data requests.
